Compounds absorbed through the skin successfully avoid hepatic first-pass metabolism, which is a primary pharmacological advantage of transdermal drug delivery.
The claim states that compounds absorbed through the skin completely bypass first-pass metabolism in the liver. Retrieved papers 8 and 9 directly support this pharmacological fact, noting that transdermal routes and patches avoid hepatic first-pass metabolism entirely. Therefore, the claim is supported.